Browsing Tag
Alector
2 posts
Novartis drops ALS drug lifonebart after Phase 2 trial misses key goals
Novartis has discontinued development of VHB937, or lifonebart, in amyotrophic lateral sclerosis after a 251-patient Phase 2 trial missed its primary and secondary objectives, adding to several recent pipeline disappointments.
AviadoBio opens fourth ASPIRE-FTD cohort as AVB-101 regains full development rights and secures fresh backing from leading dementia foundations
AviadoBio opens the fourth ASPIRE-FTD cohort, regains full AVB-101 rights from Astellas, and secures ADDF backing. Read what it means for FTD gene therapy.